OXiGENE (OXGN): ZYBRESTAT Plus Avastin Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Trial

By smallcapbiotech

February 7, 2013

Comments Off on OXiGENE (OXGN): ZYBRESTAT Plus Avastin Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Trial

OXiGENE, Inc. (Nasdaq :OXGN)  is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions. OXGN announced that the randomized Phase 2 study evaluating the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) to …Read More

Exelixis (EXEL): CEO to Present at the 15th Annual BIO CEO and Investor Conference

By smallcapbiotech

February 6, 2013

Comments Off on Exelixis (EXEL): CEO to Present at the 15th Annual BIO CEO and Investor Conference

Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ (cabozantinib) and has also established a portfolio of other novel compounds, many of which are being advanced by partners as part of collaborations. Michael …Read More

EDAP TMS SA (EDAP): Submission of PMA Application to the U.S. FDA

By smallcapbiotech

February 1, 2013

Comments Off on EDAP TMS SA (EDAP): Submission of PMA Application to the U.S. FDA

EDAP TMS SA (EDAP) is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers. EDAP announced today the submission of its Pre-Market Approval (PMA) …Read More

CEL-SCI Corp (CVM): New Investigational Breast Cancer Vaccine

By smallcapbiotech

January 31, 2013

Comments Off on CEL-SCI Corp (CVM): New Investigational Breast Cancer Vaccine

CEL-SCI Corporation (CVM) is a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company’s core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI announced that its longstanding collaboration with Northeast Ohio Medical …Read More

ARCA biopharma, Inc. (ABIO): Phase 3 Trial for Gencaro in Atrial Fibrillation

By smallcapbiotech

January 29, 2013

Comments Off on ARCA biopharma, Inc. (ABIO): Phase 3 Trial for Gencaro in Atrial Fibrillation

ARCA biopharma, Inc. (NASDAQ: ABIO) is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation and treatment of heart failure in patients with heart failure and reduced left ventricular ejection fraction …Read More

Keryx Biopharmaceuticals (KERX): Zerenex Meets Primary and All Key Secondary Endpoints in Phase 3 Study

By smallcapbiotech

January 28, 2013

Comments Off on Keryx Biopharmaceuticals (KERX): Zerenex Meets Primary and All Key Secondary Endpoints in Phase 3 Study

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. KERX today announced that its ferric iron-based phosphate …Read More

Idenix Pharmaceuticals (IDIX): Collaboration With Janssen to Initiate Phase II Simeprevir, IDX719 and TMC647055 Studies

By smallcapbiotech

January 28, 2013

Comments Off on Idenix Pharmaceuticals (IDIX): Collaboration With Janssen to Initiate Phase II Simeprevir, IDX719 and TMC647055 Studies

Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Building on its expertise in nucleoside chemistry and other small molecule chemistry and biology, the company is well positioned to become a leader in antiviral pharmaceuticals. Idenix’s current focus is on …Read More

Celsion (CLSN): Cash and Incentives up to $100 Million

By smallcapbiotech

January 27, 2013

Comments Off on Celsion (CLSN): Cash and Incentives up to $100 Million

Celsion (NASDAQ: CLSN) is developing a ThermoDox, a treatment for primary liver cancer. The company combines radio-frequency thermal ablation (RFA) with a high dose of the drug doxorubin. ThermoDox targets a specific area and then cover the tumor through the process of heating the accumulated drug. Phase III results show that ThermoDox with RFA treatment improves the …Read More

Kips Bay Medical (KIPS): FDA Approval for eMESH Additional US Study

By smallcapbiotech

January 25, 2013

Comments Off on Kips Bay Medical (KIPS): FDA Approval for eMESH Additional US Study

Kips Bay Medical,Inc. (NASDAQ: KIPS) is dedicated to providing therapeutic vascular technologies for the cardiac surgeon to better treat cardiovascular disease. Recently KIPS announced that the United States Food & Drug Administration (FDA) has granted approval for additional US patients to be enrolled in Kips Bay Medicals eMESH I clinical feasibility trial of its eSVS …Read More

Protalix BioTherapeutics (PLX): Offer of Potential All-Cash Acquisition

By smallcapbiotech

January 25, 2013

Comments Off on Protalix BioTherapeutics (PLX): Offer of Potential All-Cash Acquisition

Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins that target large, established pharmaceutical markets and that rely …Read More